Ц.Билэгтсайхан
Loading...
Товч нэр
Ц.Билэгтсайхан
Бүтэн нэр
Цолмон Билэгтсайхан
Латин нэр
Tsolmon Bilegtsaikhan
Албан тушаал
Проректор
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis(2024-03) ;Fagerli, Kirsten ;Ulziibayar, Munkhchuluun ;Suuri, Bujinlkham ;Luvsantseren, DashtserenNarangerel, DorjBACKGROUND: Few studies have assessed the potential indirect effects of childhood pneumococcal conjugate vaccine (PCV) programs on the adult pneumonia burden in resource-limited settings. We evaluated the impact of childhood PCV13 immunisation on adult all-cause pneumonia following a phased program introduction from 2016. METHODS: We conducted a time-series analysis to assess changes in pneumonia hospitalisation incidence at four district hospitals in Mongolia. Adults (≥18 years) that met the clinical case definition for all-cause pneumonia were enrolled. A negative binomial mixed-effects model was used to assess the impact of PCV13 introduction on monthly counts of pneumonia admissions from January 2015-February 2022. We also performed a restricted analysis excluding the COVID-19 pandemic period. All models were stratified by age and assessed separately. Additional analyses assessed the robustness of our findings. FINDINGS: The average annual incidence of all-cause pneumonia hospitalisation was highest in adults 65+ years (62.81 per 10,000 population) and declined with decreasing age. After adjusting for the COVID-19 pandemic period, we found that rates of pneumonia hospitalisation remained largely unchanged over time. We did not observe a reduction in pneumonia hospitalisation in any age group. Results from restricted and sensitivity analyses were comparable to the primary results, finding limited evidence of a reduced pneumonia burden. INTERPRETATION: We did not find evidence of indirect protection against all-cause pneumonia in adults following childhood PCV13 introduction. Direct pneumococcal vaccination and other interventions should be considered to reduce burden of pneumonia among older adults. FUNDING: Pfizer clinical research collaboration agreement (contract number: WI236621).Scopus© Citations 5
